Amedisys (AMED) Tops Q2 EPS by 2c

Amedisys (NASDAQ: AMED) reported Q2 EPS of $1.69, $0.02 better than the analyst estimate of $1.67. Revenue for the quarter came in at $564.2 million versus the consensus estimate of $566.19 million.

GUIDANCE:

Amedisys sees Q3 2021 EPS of $6.37-$6.49, versus the consensus of $6.96. Amedisys sees Q3 2021 revenue of $2.23-2.245 billion, versus the consensus of $2.32 billion.

For earnings history and earnings-related data on Amedisys (AMED) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs